Simone, oncology polymath and leader

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Joe Simone was oncology’s polymath. Skilled and adept in patient care, scientific and clinical discovery, administrative leadership, education as well as mentoring to a generation of oncologists through his writings.

00003893-005
Simone with a patient at St. Jude Children’s Research Hospital in 1970. Photo courtesy of St. Jude Children’s Research Hospital.

Over the years we worked together on many shared endeavors including the National Comprehensive Cancer Network, the Huntsman Cancer Institute, and many cancer policymaking organizations. He was forever creative, insightful and astute.

But Joe’s genuine affection and respect for his colleagues and friends spilled over into everything he did.

Joe and I ran for president of ASCO in the same year. With the organization heavily weighted toward medical oncologists rather than pediatricians, that more than anything else enabled me to win.

Shortly after the election I received a handwritten letter from Joe. It said, in essence, that although he had hoped he would win, he was very pleased to see me in that role and hoped that we would have many opportunities to work together in the future.

Thirty years later, I still have that letter. Joe made a lasting impact on oncology and as well as on so many of his colleagues.

He will remain forever in the lives of so many of us.


The author is the former president, chief executive officer, and chancellor,

Fox Chase Cancer Center


Joseph V. Simone’s book, “Simone’s Maxims,” is available for download through the Cancer History Project.

Robert C. Young, MD
Former president, chief executive officer, and chancellor, Fox Chase Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
Robert C. Young, MD
Former president, chief executive officer, and chancellor, Fox Chase Cancer Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login